Page 187 - Drug Class Review
P. 187
Drug Effectiveness Review Project
placebo (P = 0.03) Groups similar at baseline: No; mean age of DON 10 mg/d group was 2 years older than Alzheimer classification: Mild-moderate placebo donepezil 10mg donepezil 5mg 72.6 74.6 72.9 61 62 63 94% 96% 95% 4% 2% 3% 2% 3% 2% 19.2 18.9 19.0 Primary Outcome Measures: ADAS-Cog; CIBIC-plus Secondary Outcome Measures: MMSE; QOL; CDR-SB Timing of assessments: Baseline and every 6 weeks Health Outcome Measures: 5 mg/d DON-treated patients showed significant improvement in QOL score compared to placebo • at week
Final Report Update 1 Authors: Rogers et al. Year: 1998 POPULATION CHARACTERISTICS: Mean age (years): Sex (% female): Ethnicity: White • Black • Other • Other germane population qualities: Mean baseline MMSE • OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs
